400 related articles for article (PubMed ID: 15496893)
1. Antibiotics at the crossroads.
Nathan C
Nature; 2004 Oct; 431(7011):899-902. PubMed ID: 15496893
[No Abstract] [Full Text] [Related]
2. Antibiotics: a shot in the arm.
Leeb M
Nature; 2004 Oct; 431(7011):892-3. PubMed ID: 15496888
[No Abstract] [Full Text] [Related]
3. Are rich nations up for drug reform?
Check E
Nature; 2006 May; 441(7090):135. PubMed ID: 16688137
[No Abstract] [Full Text] [Related]
4. World's first nonprofit drug company launched.
Cassels A
CMAJ; 2003 Sep; 169(6):590. PubMed ID: 12975232
[No Abstract] [Full Text] [Related]
5. The antibacterial drugs market.
Kresse H; Belsey MJ; Rovini H
Nat Rev Drug Discov; 2007 Jan; 6(1):19-20. PubMed ID: 17269159
[No Abstract] [Full Text] [Related]
6. Busting the billion-dollar myth: how to slash the cost of drug development.
Maxmen A
Nature; 2016 Aug; 536(7617):388-90. PubMed ID: 27558048
[No Abstract] [Full Text] [Related]
7. Public-private partnerships boost research on neglected diseases.
Louët S
Nat Biotechnol; 2003 Nov; 21(11):1254-5. PubMed ID: 14595339
[No Abstract] [Full Text] [Related]
8. More drugs, less protection.
Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
[No Abstract] [Full Text] [Related]
9. Global trends in the pharmaceutical industry.
Albers-Schönberg G
P R Health Sci J; 2002 Jun; 21(2):85-9. PubMed ID: 12166029
[No Abstract] [Full Text] [Related]
10. TB drug prices slashed for poor countries.
Hagmann M
Bull World Health Organ; 2001; 79(9):904-5. PubMed ID: 11584747
[No Abstract] [Full Text] [Related]
11. Drug companies snub antibiotics as pipeline threatens to run dry.
Clarke T
Nature; 2003 Sep; 425(6955):225. PubMed ID: 13679874
[No Abstract] [Full Text] [Related]
12. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
13. The urgent need for new antibacterial agents.
Wise R;
J Antimicrob Chemother; 2011 Sep; 66(9):1939-40. PubMed ID: 21700627
[No Abstract] [Full Text] [Related]
14. [The production of pharmaceuticals in the world will become polarized].
Eränkö P
Duodecim; 2003; 119(17):1605-6. PubMed ID: 14587438
[No Abstract] [Full Text] [Related]
15. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
16. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
[TBL] [Abstract][Full Text] [Related]
17. [Progress of medicine threatened by drug resistance].
Sante; 2000; 10(5):363-4. PubMed ID: 11221700
[No Abstract] [Full Text] [Related]
18. Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?
Nielsen TB; Brass EP; Gilbert DN; Bartlett JG; Spellberg B
N Engl J Med; 2019 Aug; 381(6):503-505. PubMed ID: 31216396
[No Abstract] [Full Text] [Related]
19. Location of pharmaceutical innovation: 2000-2009.
Friedman Y
Nat Rev Drug Discov; 2010 Nov; 9(11):835-6. PubMed ID: 21030994
[No Abstract] [Full Text] [Related]
20. Vaccine venture boosts health hopes.
Butler D
Nature; 2009 Sep; 461(7262):323. PubMed ID: 19759588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
